Amicus Therapeutics Files 8-K
Ticker: FOLD · Form: 8-K · Filed: Feb 21, 2025 · CIK: 1178879
| Field | Detail |
|---|---|
| Company | Amicus Therapeutics, Inc. (FOLD) |
| Form Type | 8-K |
| Filed Date | Feb 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financial-statements
TL;DR
Amicus Therapeutics filed a standard 8-K, mostly exhibits. No major news.
AI Summary
On February 21, 2025, Amicus Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosures rather than a specific material event. No significant financial figures or new strategic developments were detailed in the provided excerpt.
Why It Matters
This filing indicates Amicus Therapeutics is making routine disclosures to the SEC, which is standard practice for publicly traded companies. It does not appear to signal any immediate material changes or events.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, suggesting no immediate material event or significant risk.
Key Players & Entities
- AMICUS THERAPEUTICS, INC. (company) — Registrant
- February 21, 2025 (date) — Date of Report
- 47 Hulfish Street (address) — Principal Executive Offices
- Princeton (location) — City
- New Jersey (location) — State
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits.
What is the exact name of the reporting company?
The exact name of the reporting company is AMICUS THERAPEUTICS, INC.
On what date was this report filed?
This report was filed on February 21, 2025.
Where are Amicus Therapeutics' principal executive offices located?
Amicus Therapeutics' principal executive offices are located at 47 Hulfish Street, Princeton, New Jersey 08542.
What is the company's IRS Employer Identification Number?
The company's IRS Employer Identification Number is 71-0869350.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 21, 2025 regarding AMICUS THERAPEUTICS, INC. (FOLD).